New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:07 EDTCNCE, JAZZ, CELGConcert Pharmaceuticals reports FY13 EPS ($4.99) vs. (16.15) last year
Concert Pharmaceuticals reports FY13 revenue $25.4M vs. $12.8M last year. The company said, "The increase in revenue was primarily due to license and research and development revenue of $17M and $3.7M recognized for the year ended December 31, 2013 in connection with collaborations entered into with Celgene (CELG) and Jazz Pharmaceuticals (JAZZ) respectively, during 2013."
News For CNCE;CELG;JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 14, 2015
12:09 EDTJAZZFlamel Technologies plunges after Jazz gets favorable patent ruling
Subscribe for More Information
January 13, 2015
16:00 EDTCELGOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
12:48 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
09:36 EDTCELGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
07:43 EDTCELGCelgene price target raised to $142 from $109 at Bernstein
Subscribe for More Information
07:24 EDTCELGCelgene 2015 guidance conservative, says Cantor
Subscribe for More Information
January 12, 2015
16:12 EDTCELGAgios announces Celgene agrees to exercise option to license AG-120
Agios Pharmaceuticals (AGIO) announced that its collaboration partner Celgene (CELG) has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act.
13:21 EDTJAZZJazz Pharmaceuticals says 2015 will include top, bottom line growth
Subscribe for More Information
13:17 EDTJAZZJazz sees 2014 Erwinaze sales at upper end of range
Subscribe for More Information
12:10 EDTCELGRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
11:09 EDTCELGCelgene sees 2020 adjusted EPS over $12.50, sales above $20B
Subscribe for More Information
11:06 EDTCELGCelgene backs FY17 target for adjusted EPS $7.50, sales $13B-$14B
Subscribe for More Information
11:03 EDTCELGCelgene sees FY15 Revlimid sales $5.6B-$5.7B
Subscribe for More Information
11:02 EDTCELGCelgene sees Q4 adjusted EPS $1.01, consensus 99c
Subscribe for More Information
11:02 EDTCELGCelgene sees FY14 adjusted EPS $3.71, consensus $3.69
Sees FY14 net product sales $7.56B, consensus $7.66B. Sees FY14 Revlimid sales $4.98B, Abraxane sales $848M, Pomalyst/Imnovid sales $680M and Otezla sales $70M.
10:59 EDTCELGCelgene sees FY15 adjusted EPS $4.60-$4.75, consensus $4.84
Subscribe for More Information
10:56 EDTCELGCelgene says no higher priority that accelerating development of Crohn's drug
Subscribe for More Information
10:53 EDTCELGCelgene says Otezla scripts accelerated in Q4
10:51 EDTCELGCelgene reports FY14 EPS $3.71, consensus $3.69
Subscribe for More Information
10:44 EDTCELGCelgene CEO says company expects to meet, exceed 2017 guidance
The company is speaking at JPMorgan's conference.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use